Related Experiment Video

Updated: May 5, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

14.5K

Role of gamma-glutamyltransferase in cardiovascular diseases

Shengyang Jiang1, Donglin Jiang, Yijia Tao

  • 1Department of Cardiology, the Third Affiliated Hospital to Nantong University, Wuxi, Jiangsu Province, China.

Experimental and Clinical Cardiology
|December 3, 2013
PubMed

Insights

Elevated levels of Gamma-glutamyltransferase (GGT) indicate a higher risk for cardiovascular diseases, including coronary artery disease and heart failure emergencies. Understanding GGT

Area of Science:

  • Biochemistry
  • Cardiology
  • Clinical Medicine

Background:

  • Cardiovascular diseases (CVDs) present a significant global health burden with increasing morbidity and mortality.
  • Gamma-glutamyltransferase (GGT) is an enzyme implicated in various physiological and pathological processes.
  • Emerging evidence suggests a link between GGT levels and the development and progression of CVDs.

Purpose of the Study:

  • To investigate the role of Gamma-glutamyltransferase (GGT) in the pathogenesis of cardiovascular diseases.
  • To explore the predictive value of GGT levels for the prognosis of cardiovascular disease.
  • To elucidate the association between GGT and cardiovascular emergencies, such as chronic heart failure.

Main Methods:

  • Literature review and meta-analysis of existing studies on GGT and cardiovascular outcomes.
  • Analysis of clinical data correlating GGT levels with cardiovascular disease incidence and mortality.
  • Biochemical pathway analysis to understand GGT's mechanism in cardiac pathophysiology.

Main Results:

  • Elevated GGT levels are independently associated with increased risk of coronary artery disease.
  • GGT levels serve as a predictive marker for cardiac death and the need for cardiac transplantation.
  • A significant correlation exists between higher GGT levels and cardiovascular emergencies in patients with chronic heart failure.

Conclusions:

  • Gamma-glutamyltransferase (GGT) is a relevant biomarker for cardiovascular disease risk and prognosis.
  • Further investigation into GGT's mechanistic role in cardiac diseases is warranted for developing novel preventive and therapeutic strategies.
  • GGT evaluation may aid in risk stratification and management of patients with or at risk for cardiovascular conditions.

Keywords:
Coronary artery diseaseGamma-glutamyltransferaseHeart failureHypertension

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.3K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
100
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
769